| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
John Neuman is Director at ICUCW, with reported holdings spanning 2 companies. John Neuman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $25K at current prices.
Our model assigns John Neuman a below-average insider score of 30/100, based on 5 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -65.8%.
John Neuman's largest disclosed position is in ICU as Director, worth about $24K. Net of sales, the ICU filings show accumulation of 80,000 shares.
John Neuman has 6 Form 4 filings on record from June 2024 to July 2026, across 2 companies: Director at SeaStar Medical (ICUCW), 2026; Director at SeaStar Medical (ICU), 2024–2026.
The 10 reported transactions were 5 open-market purchases, 3 stock awards, 1 option exercise and 1 option or other derivative award.
Counted by filing, the open-market trades come to 2 purchases worth about $168K and no sales.
The largest open-market purchase was 40,000 shares of ICU at an average $3.83 on December 11, 2024, about $153K. Twelve months later ICU was down 84%.